Page last updated: 2024-08-22

trimetazidine and Macular Degeneration

trimetazidine has been researched along with Macular Degeneration in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fischer, T	2
Bourgeois, H; Chaine, G; Cohen, SY; Corbe, C; Espinasse-Berrod, MA; Garcia-Sanchez, J; Gaudric, A; Hullo, A; Leys, A; Sahel, J; Soubrane, G	1

Reviews

2 review(s) available for trimetazidine and Macular Degeneration

Article	Year
[Pharmacological therapy of age-related macular degeneration based on etiopathogenesis]. Orvosi hetilap, 2015, Nov-15, Volume: 156, Issue:46 Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Aspirin; Bosentan; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infliximab; Lutein; Macular Degeneration; Melatonin; PPAR gamma; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Resveratrol; Stilbenes; Sulfonamides; Trimetazidine; Tumor Necrosis Factor-alpha; Ubiquinone; Vitamin D; Xanthophylls	2015
[New possibilities in the pharmacologic prevention of age-related macular degeneration]. Orvosi hetilap, 2008, Jan-20, Volume: 149, Issue:3 Topics: Adrenergic Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macular Degeneration; Oxidative Stress; Platelet Aggregation Inhibitors; Primary Prevention; Risk Factors; Trimetazidine; Vasodilation; Vasodilator Agents	2008

Article

Year

[Pharmacological therapy of age-related macular degeneration based on etiopathogenesis].

Orvosi hetilap, 2015, Nov-15, Volume: 156, Issue:46

Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Aspirin; Bosentan; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infliximab; Lutein; Macular Degeneration; Melatonin; PPAR gamma; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Resveratrol; Stilbenes; Sulfonamides; Trimetazidine; Tumor Necrosis Factor-alpha; Ubiquinone; Vitamin D; Xanthophylls

2015

[New possibilities in the pharmacologic prevention of age-related macular degeneration].

Orvosi hetilap, 2008, Jan-20, Volume: 149, Issue:3

Topics: Adrenergic Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macular Degeneration; Oxidative Stress; Platelet Aggregation Inhibitors; Primary Prevention; Risk Factors; Trimetazidine; Vasodilation; Vasodilator Agents

2008

Trials

1 trial(s) available for trimetazidine and Macular Degeneration

Article	Year
Randomized clinical trial France DMLA2: effect of trimetazidine on exudative and nonexudative age-relatedmacular degeneration. Retina (Philadelphia, Pa.), 2012, Volume: 32, Issue:4 Topics: Aged; Aged, 80 and over; Belgium; Choroidal Neovascularization; Double-Blind Method; Exudates and Transudates; Female; Follow-Up Studies; France; Humans; Macular Degeneration; Male; Middle Aged; Spain; Trimetazidine; Vasodilator Agents	2012

Article

Year

Randomized clinical trial France DMLA2: effect of trimetazidine on exudative and nonexudative age-relatedmacular degeneration.

Retina (Philadelphia, Pa.), 2012, Volume: 32, Issue:4

Topics: Aged; Aged, 80 and over; Belgium; Choroidal Neovascularization; Double-Blind Method; Exudates and Transudates; Female; Follow-Up Studies; France; Humans; Macular Degeneration; Male; Middle Aged; Spain; Trimetazidine; Vasodilator Agents

2012